ELLAGRIN / SHUTTERSTOCK.COM
It is unclear whether the so-called new therapeutic entities are qualified to be patented under current Mexican IP laws. Soledad Betanzos-Lara of Goodrich, Riquelme y Asociados examines the current landscape.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
NTEs, patent, generics, New therapeutic entities, supergenerics
